Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Benchmark analyst Robert Wasserman downgrades AbCellera Biologics (NASDAQ:ABCL) from Buy to Hold.
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $...
AbCellera (NASDAQ:ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to d...
Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and lowers the price target f...
Keybanc analyst Scott Schoenhaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and lowers the price target f...
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $...
Data show how AbCellera is expanding the reach of T-cell engagers with:CD3-binding antibodies that consistently generate T-cell...
AbCellera (NASDAQ:ABCL) and Biogen Inc. (NASDAQ:BIIB) have entered into a strategic collaboration to discover antibodies for a ...
